LEGN
Legend Biotech Corporation · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -13.3% ·
share flow +5.2% ·
net new positions -15.4%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 92 | +12 | 61.78M | $1.78B | +17 | −5 |
| Q1 2026 | 82 | -3 | 51.41M | $929.52M | +5 | −8 |
| Q4 2025 | 86 | +2 | 50.21M | $1.09B | +2 | — |
| Q3 2025 | 13 | -2 | 38.53M | $1.26B | — | −2 |
| Q2 2025 | 12 | -1 | 34.51M | $1.22B | +1 | −2 |
| Q1 2025 | 10 | 0 | 13.38M | $453.85M | — | — |
| Q4 2024 | 10 | -1 | 15.80M | $514.13M | — | −1 |
| Q3 2024 | 10 | +3 | 16.52M | $804.74M | +3 | — |
| Q2 2024 | 7 | — | 18.35M | $812.58M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 27.70M | +7.9% | $903.39M | 0.0% | ▲ Add | 2 | SEC ↗ ×8 |
| 2 | BlackRock ✦ (passive) | 4.49M | +5.8% | $146.57M | 0.0% | ▲ Add | 2 | SEC ↗ ×17 |
| 3 | State Street Global Advisors ✦ (passive) | 1.16M | +3.3% | $37.73M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Goldman Sachs Group ✦ | 1.06M | — | $34.42M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | Renaissance Technologies ✦ | 843.20K | +28.5% | $27.50M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 6 | Millennium Management ✦ | 792.49K | +7.0% | $25.84M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 7 | JPMorgan Chase ✦ | 619.21K | — | $20.19M | 0.0% | n/c | 1 | SEC ↗ ×14 |
| 8 | Geode Capital Management ✦ (passive) | 540.04K | +14.0% | $17.46M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | Morgan Stanley ✦ | 431.08K | — | $14.06M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 10 | Citadel Advisors ✦ | 382.81K | +131.9% | $12.48M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 11 | Two Sigma Investments ✦ | 359.94K | +33.5% | $11.74M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 12 | The Vanguard Group ✦ (passive) | 137.60K | +12.8% | $4.49M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 13 | Marshall Wace ✦ | 17.87K | +30.6% | $582,806 | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| T. Rowe Price | $28.40M | was 0.0% |
| Point72 Asset Management | $8.09M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 189 holders, 95.78M shares, $1.69B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 27.37K sh · $258,920
Officer · 5.43K sh · $49,630
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology